Order Article Reprints

Puttemans J, Dekempeneer Y, Eersels JL, Hanssens H, Debie P, Keyaerts M, Windhorst AD, van der Aa F, Lecocq Q, Breckpot K, et al. Preclinical Targeted α- and β⁻-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies. Cancers. 2020; 12(4):1017. https://doi.org/10.3390/cancers12041017

Puttemans, Janik, Yana Dekempeneer, Jos L. Eersels, Heleen Hanssens, Pieterjan Debie, Marleen Keyaerts, Albert D. Windhorst, Frank van der Aa, Quentin Lecocq, Karine Breckpot, and et al. 2020. "Preclinical Targeted α- and β⁻-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies" Cancers 12, no. 4: 1017. https://doi.org/10.3390/cancers12041017

Puttemans, J., Dekempeneer, Y., Eersels, J. L., Hanssens, H., Debie, P., Keyaerts, M., Windhorst, A. D., van der Aa, F., Lecocq, Q., Breckpot, K., Morgenstern, A., Bruchertseifer, F., Lahoutte, T., Devoogdt, N., & D’Huyvetter, M. (2020). Preclinical Targeted α- and β⁻-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies. Cancers, 12(4), 1017. https://doi.org/10.3390/cancers12041017